Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2

Non-small cell lung cancer (NSCLC) is known to have poor patient outcomes due to development of resistance to chemotherapy agents and the EGFR inhibitors, which results in recurrence of highly aggressive lung tumors. Even with recent success in immunotherapy using the checkpoint inhibitors, addition...

Descripción completa

Detalles Bibliográficos
Autores principales: Bora-Singhal, Namrata, Mohankumar, Durairaj, Saha, Biswarup, Colin, Christelle M., Lee, Jennifer Y., Martin, Matthew W., Zheng, Xiaozhang, Coppola, Domenico, Chellappan, Srikumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069992/
https://www.ncbi.nlm.nih.gov/pubmed/32170113
http://dx.doi.org/10.1038/s41598-020-61295-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069992/
https://www.ncbi.nlm.nih.gov/pubmed/32170113
http://dx.doi.org/10.1038/s41598-020-61295-6

Ejemplares similares